Biologix is a Dubai-based firm that represents international pharma companies by bringing innovative drugs to market in the Middle East / North Africa (MENA) region. Its GM, Zeina Sfeir Lahoud, discusses the company’s presence in over 17 countries, their 25 years of experience in Saudi Arabia, and the dynamics shaping the largest market in the region, including the fast regulatory approval process in place. With value-based healthcare an increasingly hot topic, she explains how Biologix has moved to sign the first risk-sharing agreement with Saudi Arabia for a spinal muscular atrophy product; the first in the MENA region.
STAY UP TO DATE NEWS & EVENTS
Related EVENTS & NEWS
Biologix proudly hosted the 4th Ironwill Summit in Dubai
Biologix's Second Sustainability Session: To Boost Greener Practices in DSP offices
Because the commitment to environmental sustainability is a journey, Biologix has conducted a second session on sustainability and CO2 reduction in partnership with D-Grade. The session was held for the Biologix people working in the Dubai Science Park offices on Thursday 26 October 2023.
Biologix Participates in the 2nd Saudi Rare Disease Summit, Advocating for Pediatric Neurology Awareness
Biologix participated in the 2nd Saudi Rare Disease Summit held in Riyadh, KSA, on February 16-17, 2024.
Focused on pediatric neurology, particularly CDKL5 Deficiency Disorder and Alpha Mannosidosis, the congress showed the importance of raising awareness and advancing understanding in this specialized field.
